Sarepta Therapeutics Stock EBITDA

SRPT Stock

USD 114.23 3.73 3.38%

Sarepta Therapeutics fundamentals help investors to digest information that contributes to Sarepta Therapeutics' financial success or failures. It also enables traders to predict the movement of Sarepta Stock. The fundamental analysis module provides a way to measure Sarepta Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sarepta Therapeutics stock.

		Last Reported	Projected for Next Year
	EBITDA	-439.2 M	-417.2 M

EBITDA is likely to gain to about (417.2 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sarepta Therapeutics Company EBITDA Analysis

Sarepta Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Sarepta Therapeutics EBITDA

(439.2 M)

Most of Sarepta Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sarepta Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Sarepta EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Sarepta Therapeutics is extremely important. It helps to project a fair market value of Sarepta Stock properly, considering its historical fundamentals such as EBITDA. Since Sarepta Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sarepta Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sarepta Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Net Receivables	Current Deferred Revenue	Long Term Debt	Short Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.79	0.34	-0.97	0.9	0.75	0.98	1.0	0.78	-0.3	0.97	0.86	0.84	0.97	0.76	0.63	0.99	0.99	0.93	0.96	0.05	0.92	0.88
Total Stockholder Equity	0.79		0.11	-0.71	0.63	0.61	0.64	0.8	0.76	-0.38	0.69	0.57	0.42	0.67	0.73	0.93	0.76	0.81	0.81	0.65	0.37	0.56	0.56
Net Debt	0.34	0.11		-0.5	0.58	0.82	0.39	0.31	0.56	-0.01	0.53	0.69	0.1	0.39	-0.1	-0.19	0.4	0.41	0.36	0.35	-0.26	0.17	0.51
Retained Earnings	-0.97	-0.71	-0.5		-0.95	-0.81	-0.97	-0.96	-0.82	0.33	-0.99	-0.93	-0.78	-0.96	-0.66	-0.5	-0.97	-0.98	-0.9	-0.96	0.08	-0.87	-0.94
Accounts Payable	0.9	0.63	0.58	-0.95		0.81	0.91	0.88	0.87	-0.26	0.97	0.96	0.71	0.86	0.64	0.36	0.92	0.92	0.86	0.9	-0.19	0.82	0.91
Short Term Investments	0.75	0.61	0.82	-0.81	0.81		0.72	0.74	0.79	-0.24	0.82	0.85	0.44	0.74	0.35	0.35	0.76	0.79	0.73	0.68	0.05	0.54	0.71
Total Liab	0.98	0.64	0.39	-0.97	0.91	0.72		0.97	0.71	-0.24	0.97	0.88	0.9	0.98	0.7	0.48	0.98	0.95	0.89	0.97	-0.06	0.95	0.91
Total Current Assets	1.0	0.8	0.31	-0.96	0.88	0.74	0.97		0.76	-0.31	0.95	0.84	0.84	0.97	0.76	0.66	0.99	0.98	0.92	0.94	0.08	0.91	0.86
Intangible Assets	0.78	0.76	0.56	-0.82	0.87	0.79	0.71	0.76		-0.35	0.82	0.88	0.44	0.67	0.6	0.47	0.8	0.83	0.72	0.72	-0.18	0.6	0.78
Common Stock	-0.3	-0.38	-0.01	0.33	-0.26	-0.24	-0.24	-0.31	-0.35		-0.27	-0.19	-0.19	-0.25	-0.19	-0.36	-0.25	-0.33	-0.26	-0.22	-0.08	-0.2	-0.19
Property Plant Equipment	0.97	0.69	0.53	-0.99	0.97	0.82	0.97	0.95	0.82	-0.27		0.94	0.79	0.95	0.67	0.47	0.97	0.98	0.92	0.96	-0.07	0.88	0.93
Net Receivables	0.86	0.57	0.69	-0.93	0.96	0.85	0.88	0.84	0.88	-0.19	0.94		0.65	0.84	0.56	0.27	0.9	0.89	0.8	0.88	-0.26	0.77	0.94
Current Deferred Revenue	0.84	0.42	0.1	-0.78	0.71	0.44	0.9	0.84	0.44	-0.19	0.79	0.65		0.85	0.73	0.35	0.81	0.76	0.68	0.86	-0.05	0.97	0.74
Long Term Debt	0.97	0.67	0.39	-0.96	0.86	0.74	0.98	0.97	0.67	-0.25	0.95	0.84	0.85		0.64	0.54	0.97	0.95	0.89	0.94	0.0	0.9	0.88
Short Term Debt	0.76	0.73	-0.1	-0.66	0.64	0.35	0.7	0.76	0.6	-0.19	0.67	0.56	0.73	0.64		0.65	0.73	0.72	0.73	0.77	0.26	0.82	0.61
Net Tangible Assets	0.63	0.93	-0.19	-0.5	0.36	0.35	0.48	0.66	0.47	-0.36	0.47	0.27	0.35	0.54	0.65		0.58	0.63	0.68	0.47	0.57	0.43	0.3
Long Term Debt Total	0.99	0.76	0.4	-0.97	0.92	0.76	0.98	0.99	0.8	-0.25	0.97	0.9	0.81	0.97	0.73	0.58		0.98	0.92	0.96	-0.04	0.9	0.91
Capital Surpluse	0.99	0.81	0.41	-0.98	0.92	0.79	0.95	0.98	0.83	-0.33	0.98	0.89	0.76	0.95	0.72	0.63	0.98		0.94	0.94	0.03	0.86	0.89
Short Long Term Debt	0.93	0.81	0.36	-0.9	0.86	0.73	0.89	0.92	0.72	-0.26	0.92	0.8	0.68	0.89	0.73	0.68	0.92	0.94		0.9	0.26	0.8	0.81
Net Invested Capital	0.96	0.65	0.35	-0.96	0.9	0.68	0.97	0.94	0.72	-0.22	0.96	0.88	0.86	0.94	0.77	0.47	0.96	0.94	0.9		-0.03	0.95	0.95
Long Term Investments	0.05	0.37	-0.26	0.08	-0.19	0.05	-0.06	0.08	-0.18	-0.08	-0.07	-0.26	-0.05	0.0	0.26	0.57	-0.04	0.03	0.26	-0.03		-0.05	-0.26
Net Working Capital	0.92	0.56	0.17	-0.87	0.82	0.54	0.95	0.91	0.6	-0.2	0.88	0.77	0.97	0.9	0.82	0.43	0.9	0.86	0.8	0.95	-0.05		0.85
Capital Stock	0.88	0.56	0.51	-0.94	0.91	0.71	0.91	0.86	0.78	-0.19	0.93	0.94	0.74	0.88	0.61	0.3	0.91	0.89	0.81	0.95	-0.26	0.85

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Sarepta Therapeutics

Ebitda Over Time

Sarepta Ebitda

Ebitda

(417.24 Million)

At this time, Sarepta Therapeutics' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Sarepta Therapeutics reported earnings before interest,tax, depreciation and amortization of (439.2 Million). This is 150.05% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 111.27% higher than that of the company.

Sarepta EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sarepta Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sarepta Therapeutics could also be used in its relative valuation, which is a method of valuing Sarepta Therapeutics by comparing valuation metrics of similar companies.

Sarepta Therapeutics is currently under evaluation in ebitda category among its peers.

Sarepta Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sarepta Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sarepta Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Sarepta Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Sarepta Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sarepta Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sarepta Therapeutics' value.

		Shares
Jpmorgan Chase & Co	2024-06-30	1.8 M
Geode Capital Management, Llc	2024-09-30	1.7 M
Deutsche Bank Ag	2024-06-30	1.6 M
Fmr Inc	2024-09-30	1.2 M
Casdin Capital, Llc	2024-09-30	1.1 M
Pictet Asset Manangement Sa	2024-06-30	957.2 K
Citadel Advisors Llc	2024-09-30	926.2 K
Norges Bank	2024-06-30	924.4 K
Jane Street Group Llc	2024-06-30	869.1 K
Blackrock Inc	2024-06-30	10.3 M
Vanguard Group Inc	2024-09-30	9 M

Sarepta Fundamentals

	Return On Equity	0.12
	Return On Asset	0.0151
	Profit Margin	0.07 %
	Operating Margin	0.05 %
	Current Valuation	11.11 B
	Shares Outstanding	95.52 M
	Shares Owned By Insiders	4.36 %
	Shares Owned By Institutions	92.00 %
	Number Of Shares Shorted	5.6 M
	Price To Earning	(20.43) X
	Price To Book	8.94 X
	Price To Sales	6.65 X
	Revenue	1.24 B
	Gross Profit	(78.07 M)
	EBITDA	(439.2 M)
	Net Income	(535.98 M)
	Cash And Equivalents	2.07 B
	Cash Per Share	23.61 X
	Total Debt	1.4 B
	Debt To Equity	3.72 %
	Current Ratio	4.36 X
	Book Value Per Share	12.79 X
	Cash Flow From Operations	(500.99 M)
	Short Ratio	7.15 X
	Earnings Per Share	1.54 X
	Price To Earnings To Growth	159.25 X
	Target Price	189.62
	Number Of Employees	1.31 K
	Beta	0.8
	Market Capitalization	10.91 B
	Total Asset	3.26 B
	Retained Earnings	(4.45 B)
	Working Capital	1.93 B
	Current Asset	434.74 M
	Current Liabilities	64.93 M
	Net Asset	3.26 B

About Sarepta Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sarepta Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sarepta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sarepta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC